Posttranslational protein modifications as gatekeepers of cancer immunogenicity
E Marchese, S Demehri - The Journal of Clinical …, 2024 - Am Soc Clin Investig
Triple-negative breast cancer (TNBC) presents a formidable challenge in oncology due to its
aggressive phenotype and the immunosuppressive nature of its tumor microenvironment …
aggressive phenotype and the immunosuppressive nature of its tumor microenvironment …
[HTML][HTML] Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
Y Zhu, A Banerjee, P Xie, AA Ivanov… - The Journal of …, 2024 - Am Soc Clin Investig
Despite widespread utilization of immunotherapy, treating immune-cold tumors remains a
challenge. Multiomic analyses and experimental validation identified the OTUD4/CD73 …
challenge. Multiomic analyses and experimental validation identified the OTUD4/CD73 …
The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer
X Liu, Z Ma, X Jing, G Wang, L Zhao, X Zhao, Y Zhang - Cancer Letters, 2024 - Elsevier
Ferroptosis is a newly defined form of programmed cell death characterized by iron-
dependent lipid peroxide accumulation and is associated with the progression of cancer …
dependent lipid peroxide accumulation and is associated with the progression of cancer …
[HTML][HTML] OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer
HW Chiu, HY Lin, J Tseng, YF Lin - Oncotarget, 2018 - ncbi.nlm.nih.gov
Paclitaxel is a first-line chemotherapeutic for patients with breast cancer, particularly triple-
negative breast cancer (TNBC). Molecular markers for predicting pathologic responses to …
negative breast cancer (TNBC). Molecular markers for predicting pathologic responses to …
OTUD1 chemosensitizes triple-negative breast cancer to doxorubicin by modulating P16 expression
T Zhou, Y Wu, D Qian, H Tang, X Liu, J Qiu… - … -Research and Practice, 2023 - Elsevier
Chemotherapy remains a critical component of triple-negative breast cancer (TNBC)
treatment; however, patients often develop resistance to chemotherapeutic agents …
treatment; however, patients often develop resistance to chemotherapeutic agents …
K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer
X Wang, X Deng, J Hu, W Zheng, D Ye, X Zhou, L Fang - Cancer Letters, 2024 - Elsevier
Immunotherapy based on PD-1/PD-L1 antagonists has been demonstrated to be efficacious
in inducing tumor remission in patients with triple-negative breast cancer (TNBC). However …
in inducing tumor remission in patients with triple-negative breast cancer (TNBC). However …
[HTML][HTML] OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression
Y Zhang, Y Fan, X Jing, L Zhao, T Liu, L Wang, L Zhang… - Cancer letters, 2021 - Elsevier
Macrophages, which are highly plastic, can be polarized to M1 or M2 subtypes according to
the diverse signals in complex microenvironment. Studies have shown the activation of YAP …
the diverse signals in complex microenvironment. Studies have shown the activation of YAP …
Single-cell transcriptome analysis reveals the M2 macrophages and exhausted T cells and intratumoral heterogeneity in triple-negative breast cancer
L Xu, C Li - Anti-Cancer Agents in Medicinal Chemistry …, 2022 - ingentaconnect.com
Background: Triple-Negative Breast Cancer (TNBC) is a highly heterogeneous and invasive
malignancy that is characterized by high recurrence and mortality rates as well as extremely …
malignancy that is characterized by high recurrence and mortality rates as well as extremely …
Let-7a/cMyc/CCAT1/miR-17–5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1
NA Selem, H Nafae, T Manie, RA Youness… - Pathology-Research and …, 2023 - Elsevier
Background Triple negative breast cancer (TNBC) is an immunogenically hot tumor. The
immune checkpoint blockades (ICBs) have been recently emerged as promising therapeutic …
immune checkpoint blockades (ICBs) have been recently emerged as promising therapeutic …
Reversing myeloid-derived suppressor cells mediated immunosuppression via p38α inhibition enhances immunotherapy efficacy in triple negative breast cancer
Q Wang, S Li, Y Dai, X Yu, Y Wang, L Li, M Yang, K Lin… - bioRxiv, 2023 - biorxiv.org
Infiltration of myeloid-derived suppressor cells (MDSCs) leads to Immunosuppressive tumor
microenvironment (TME), which is one of the major causes for low objective response rates …
microenvironment (TME), which is one of the major causes for low objective response rates …